Japanese investors offered new opportunity to purchase life-saving vaccine bonds

Restricted Access Library

The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.

Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.

The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.

The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.

Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.

This is the third vaccine bond issue that HSBC has arranged following successful issues in 2009 and 2010 that raised a total of USD 300 million.

Investors will be offered a 3-year fixed-rate South African rand-denominated bond, a 4.5-year fixed-rate Australian dollar-denominated bond and a 15-year South African rand-denominated deep-discount bond (see below for further details). The total amount of the issuance in USD equivalent is 131 million.

Summary of Expected Terms

 

4.5-year AUD

15-year ZAR

3-year ZAR

Currency and Amount

AUD 11.5 million

ZAR 520 million

ZAR 471 million

Approximate USD Equivalent Amounts

USDeq. 11million

USDeq. 30 million
(initial notional)
USDeq. 63 million
(final notional)

USDeq. 57million

Settlement Date:

June 28, 2012

Maturity date:

December 28, 2016

June 29, 2027

June 29, 2015

Issue price:

100%

47.59%

100%

Denomination:

AUD 1,000

ZAR 50,000

ZAR 10,000

Coupon (semi-annual payment):

3.15%

0.50%

4.21%

Listing:

Luxembourg

Saving lives through Vaccine Bonds

IFFIm vaccine bonds provide investors the unique opportunity to invest their savings and help save the lives of children in developing countries by supporting immunisation, health systems strengthening and vaccine procurement programs.

Funds raised by the issuance of the bonds will be used to support health and immunisation programmes in the world’s poorest countries through the GAVI Alliance.

In its first decade, the GAVI Alliance has helped immunise more than 326 million children and save more than 5.5 million lives by accelerating access to immunisation.

The GAVI Alliance, with IFFIm’s support, is now working to save an additional 3.9 million lives as part of the effort under the United Nations Millennium Development Goals to reduce child mortality two-thirds by 2015.

IFFIm is supported by the governments of the United Kingdom, France, Italy, Spain, Australia, the Netherlands, Sweden, Norway and South Africa, which have pledged to contribute long-term financial support. The proceeds of these pledges are used, among other things, to repay the initial investments plus return.

“Through IFFIm’s vaccine bonds, Japanese investors have helped support the critically important work of immunising millions of children in the world’s poorest countries through the GAVI Alliance,” says IFFIm Chair René Karsenti. “IFFIm is an extremely efficient and innovative way to promote this cause.”

Kenichi Tatsuzawa, Chief Executive Officer, HSBC Securities (Japan) Limited said, “We are delighted to once again have the opportunity to support IFFIm in offering this bond to Japanese investors nationwide. This issue highlights Japanese investors’ strong interest in helping to contribute to improvements in health and social conditions in some of the world’s poorest economies.”

The bonds are scheduled to be available at the following distributors (listed alphabetically) during the respective offer periods:

Offer period: 1 June – 27 June 2012 

3-year fixed-rate South African rand-denominated bond, a 4.5-year fixed-rate Australian dollar-denominated bond 

Awa Securities Co., Ltd., Banyo Securities Co., Ltd., Ichiyoshi Securities Co., Ltd., Imamura Securities Co., Ltd., Rakuten Securities, Inc., Shinwa Securities Co., Ltd., Toyo Securities Co., Ltd., Yamawa Securities Co., Ltd.

Offer period: 4 June – 27 June 2012 

15-year South African rand-denominated deep-discount bond 

Ando Securities Co., Ltd


About the HSBC Group 

HSBC Holdings plc, the parent company of the HSBC Group, is headquartered in London. The Group serves customers worldwide from around 7,200 offices in over 80 countries and territories in Europe, the Asia-Pacific region, North and Latin America, the Middle East and Africa. With assets of US$2,556bn at 31 December 2011, HSBC is one of the world’s largest banking and financial services organisations.

About the GAVI Alliance 

The GAVI Alliance is a Geneva-base public-private partnership committed to saving children's lives and protecting people's health by increasing access to immunisation in the world’s poorest countries. The Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society, the Bill & Melinda Gates Foundation and other private philanthropists.

About IFFIm 

The International Finance Facility for Immunisation Company (IFFIm) was initiated in 2006 to rapidly accelerate the availability and predictability of funds for immunisation. IFFIm sells bonds in the capital markets to raise funds for the GAVI Alliance, a public-private partnership which works to save children’s lives and protect people’s health by increasing access to vaccination in developing countries. The World Bank is IFFIm’s treasury manager. IFFIm has been rated Aaa (stable outlook)by Moody’s Investor Service, AAA (negative outlook) by Fitch Ratings, and AA+ (negative outlook) by Standard & Poor’s, based on support from its donors, the United Kingdom, France, Italy, Spain, Australia, the Netherlands, Sweden, Norway and South Africa.

About the World Bank 

The World Bank is a global development cooperative owned by 188member countries. Its purpose is to help its members achieve equitable and sustainable economic growth in their national economies and to find effective solutions to pressing regional and global problems in economic development and environmental sustainability. The goal is to help overcome poverty and improve standards of living for people worldwide. The International Bank for Reconstruction and Development (IBRD), rated Aaa/AAA (Moody's/S&P), is the oldest and largest entity in the World Bank Group and provides funding, risk management tools and credit enhancement to sovereigns. To fund this activity, IBRD has been issuing debt securities in the international capital markets for 60 years. The World Bank is also the Treasury Manager for IFFIm. In that capacity, the World Bank, as IFFIm's agent, manages IFFIm's finances according to prudent policies and standards. This includes IFFIm's funding strategy and its implementation in the capital markets, rating agency and investor outreach, hedging transactions and investment management. The World Bank also coordinates with IFFIm's donors and manages their pledges and payments as well as IFFIm's disbursements for immunisation and health programmes through the GAVI Alliance.


The securities referred to in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under the securities legislation of any state of the United States, and may not be offered or sold in the United States, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. IFFIm does not presently intend to make a public offer of securities in the United States or to register any securities under the Securities Act. The securities referred to in this document will only be offered or sold outside the United States in offshore transactions in reliance on Regulation S under the Securities Act.

1.5 million

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

WHO

More facts...

close icon

modal window here